The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 4, Pages 929
Publisher
MDPI AG
Online
2020-04-10
DOI
10.3390/cancers12040929
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Febuxostat administration for the prevention of tumour lysis syndrome: A meta‐analysis
- (2019) Ioannis Bellos et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Reactive Oxygen Species in Osteoclast Differentiation and Possible Pharmaceutical Targets of ROS-Mediated Osteoclast Diseases
- (2019) Taiwo Samuel Agidigbi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Impact of ROS Generated by Chemical, Physical, and Plasma Techniques on Cancer Attenuation
- (2019) Sarmistha Mitra et al. Cancers
- Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms
- (2019) Maamoun Fatfat et al. LIFE SCIENCES
- Regulator of G protein signaling 12 enhances osteoclastogenesis by suppressing Nrf2-dependent antioxidant proteins to promote the generation of reactive oxygen species
- (2019) Andrew Ying Hui Ng et al. eLife
- Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling
- (2018) Ying Wang et al. JOURNAL OF CELL BIOLOGY
- Pathogenesis of bone disease in multiple myeloma: from bench to bedside
- (2018) Evangelos Terpos et al. Blood Cancer Journal
- Lutein Suppresses Oxidative Stress and Inflammation by Nrf2 Activation in an Osteoporosis Rat Model
- (2018) Hongtao Li et al. MEDICAL SCIENCE MONITOR
- Role of reactive oxygen species in the anticancer activity of botanicals: Comparing sensitivity profiles
- (2017) Zoya Cohen et al. Oncology Letters
- Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes
- (2017) Mari C. Asensio-López et al. PLoS One
- Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice
- (2017) Maimaiti Yisireyili et al. Scientific Reports
- Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma
- (2016) Jumpei Teramachi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol
- (2016) Kazuo Tamura et al. International Journal of Clinical Oncology
- SOD2 and Sirt3 Control Osteoclastogenesis by Regulating Mitochondrial ROS
- (2016) Haemin Kim et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Estrogen Replacement Reduces Oxidative Stress in the Rostral Ventrolateral Medulla of Ovariectomized Rats
- (2016) Fan Hao et al. Oxidative Medicine and Cellular Longevity
- Role of ROS and RNS Sources in Physiological and Pathological Conditions
- (2016) Sergio Di Meo et al. Oxidative Medicine and Cellular Longevity
- Cancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications
- (2015) S. D’Oronzo et al. CANCER TREATMENT REVIEWS
- Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases
- (2015) Danielle A. Callaway et al. JOURNAL OF BONE AND MINERAL METABOLISM
- Double Stranded RNA-Dependent Protein Kinase is Necessary for TNF-α-Induced Osteoclast Formation In Vitro and In Vivo
- (2015) Hiroki Shinohara et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma
- (2014) M Hiasa et al. LEUKEMIA
- Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome
- (2014) MIHOKO TAKAI et al. Oncology Letters
- Febuxostat, an Inhibitor of Xanthine Oxidase, Suppresses Lipopolysaccharide-Induced MCP-1 Production via MAPK Phosphatase-1-Mediated Inactivation of JNK
- (2013) Johji Nomura et al. PLoS One
- Correction: Doxorubicin-Mediated Bone Loss in Breast Cancer Bone Metastases Is Driven by an Interplay between Oxidative Stress and Induction of TGFβ
- (2013) Tapasi Rana et al. PLoS One
- Bone Marrow Stromal Cells Derived MCP-1 Reverses the Inhibitory Effects of Multiple Myeloma Cells on Osteoclastogenesis by Upregulating the RANK Expression
- (2013) Zhiqiang Liu et al. PLoS One
- Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion
- (2011) Guenther G. Steger et al. Therapeutic Advances in Medical Oncology
- Role of mitochondrial reactive oxygen species in osteoclast differentiation
- (2010) Satish Srinivasan et al. Annals of the New York Academy of Sciences
- Crosstalk of reactive oxygen species and NF-κB signaling
- (2010) Michael J Morgan et al. CELL RESEARCH
- Reactive oxygen species in cancer
- (2010) Geou-Yarh Liou et al. FREE RADICAL RESEARCH
- The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
- (2010) Michael A Becker et al. ARTHRITIS RESEARCH & THERAPY
- Review: Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?
- (2009) Michael Gnant et al. Therapeutic Advances in Medical Oncology
- RANK ligand as a therapeutic target for bone metastases and multiple myeloma
- (2007) G. David Roodman et al. CANCER TREATMENT REVIEWS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started